TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.51M | 3.08M | 2.17M | 665.00K | 1.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.51M | 3.08M | 2.17M | 665.00K | 1.05M |
| Cost of Revenue | 31.69M | 32.63M | 29.79M | -73.15M | 26.26M |
| Gross Profit | -29.18M | -29.56M | -27.62M | 73.82M | -25.21M |
| SG&A Expenses | 7.87M | 9.10M | 8.63M | 8.02M | 7.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.56M | 41.73M | 38.42M | 37.38M | 33.67M |
| Operating Income | -37.05M | -38.65M | -36.25M | -36.71M | -32.62M |
| Income Before Tax | -35.71M | -36.95M | -34.13M | -35.81M | -29.89M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.71M | -36.95M | -34.13M | -35.81M | -29.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.71M | -36.95M | -34.13M | -35.81M | -29.89M |
| EBIT | -37.05M | -38.65M | -36.25M | -36.71M | -32.62M |
| EBITDA | -36.29M | -37.96M | -35.57M | -36.00M | -31.60M |
| EPS Basic | -0.63 | -0.65 | -0.60 | -0.63 | -0.56 |
| Normalized Basic EPS | -0.39 | -0.41 | -0.38 | -0.38 | -0.35 |
| EPS Diluted | -0.63 | -0.65 | -0.60 | -0.63 | -0.56 |
| Normalized Diluted EPS | -0.39 | -0.41 | -0.38 | -0.38 | -0.35 |
| Average Basic Shares Outstanding | 56.75M | 56.75M | 56.59M | 56.59M | 53.35M |
| Average Diluted Shares Outstanding | 56.75M | 56.75M | 56.59M | 56.59M | 53.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |